Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic - PubMed (original) (raw)
. 2020 Aug 21;369(6506):993-999.
doi: 10.1126/science.abb4255.
Chenguang Yu # 1 2, Vincent F Vartabedian # 3, Ying Jia # 1 3, Manoj Kumar 2, Ana M Gamo 2, William Vernier 2, Sabrina H Ali 1, Mildred Kissai 1, Daniel C Lazar 3, Nhan Nguyen 3, Laura E Pereira 1, Brent Benish 2, Ashley K Woods 2, Sean B Joseph 2, Alan Chu 2, Kristen A Johnson 2, Philipp N Sander 1, Francisco Martínez-Peña 1, Eric N Hampton 2, Travis S Young 2, Dennis W Wolan 4, Arnab K Chatterjee 2, Peter G Schultz 1 2, H Michael Petrassi # 5, John R Teijaro 6, Luke L Lairson 7
Affiliations
- PMID: 32820126
- DOI: 10.1126/science.abb4255
Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic
Emily N Chin et al. Science. 2020.
Abstract
Stimulator of interferon genes (STING) links innate immunity to biological processes ranging from antitumor immunity to microbiome homeostasis. Mechanistic understanding of the anticancer potential for STING receptor activation is currently limited by metabolic instability of the natural cyclic dinucleotide (CDN) ligands. From a pathway-targeted cell-based screen, we identified a non-nucleotide, small-molecule STING agonist, termed SR-717, that demonstrates broad interspecies and interallelic specificity. A 1.8-angstrom cocrystal structure revealed that SR-717 functions as a direct cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic that induces the same "closed" conformation of STING. SR-717 displayed antitumor activity; promoted the activation of CD8+ T, natural killer, and dendritic cells in relevant tissues; and facilitated antigen cross-priming. SR-717 also induced the expression of clinically relevant targets, including programmed cell death 1 ligand 1 (PD-L1), in a STING-dependent manner.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Comment in
- Immunotherapy with a sting.
Gajewski TF, Higgs EF. Gajewski TF, et al. Science. 2020 Aug 21;369(6506):921-922. doi: 10.1126/science.abc6622. Science. 2020. PMID: 32820113 No abstract available. - Strengthening the sting of immunotherapy.
Crunkhorn S. Crunkhorn S. Nat Rev Drug Discov. 2020 Oct;19(10):669. doi: 10.1038/d41573-020-00148-3. Nat Rev Drug Discov. 2020. PMID: 32843723 No abstract available. - Strengthening the sting of immunotherapy.
Crunkhorn S. Crunkhorn S. Nat Rev Immunol. 2020 Oct;20(10):589. doi: 10.1038/s41577-020-00447-1. Nat Rev Immunol. 2020. PMID: 32901152 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials